Gonadal dysfunction in patients receiving chemotherapy for cancer

Area of Science:

• Oncology
• Reproductive Medicine
• Toxicology

Background:

• Antineoplastic chemotherapy has improved cancer survival rates for various malignancies.
• Long-term survivors face risks of persistent or delayed toxicities from cancer treatments.
• Gonadal toxicity and infertility are significant concerns for patients treated with chemotherapy.

Purpose of the Study:

• To review clinical syndromes of chemotherapy-related gonadal toxicity.
• To correlate drug classes, doses, and combinations with gonadal injury and recovery potential.
• To examine age-dependent effects of chemotherapy on germ cell production and endocrine function.

Main Methods:

• Review of clinical syndromes associated with chemotherapy-induced gonadal toxicity.
• Analysis of drug-specific effects on gonadal function.
• Examination of age-related variations in chemotherapy's impact on reproductive health.

Main Results:

• Chemotherapy frequently leads to gonadal toxicity and infertility in men, women, and children.
• The degree of gonadal injury and potential for recovery depend on specific drug classes, doses, and combinations.
• Patient age at the time of treatment influences the drug effects on germ cell production and endocrine function.

Conclusions:

• Understanding chemotherapy's impact on gonadal function is crucial for long-term cancer survivors.
• Further prospective studies are needed to assess fertility, teratogenesis, and mutagenesis in these patients.
• Management strategies should consider age-specific risks and potential for reproductive recovery.